Stockreport

Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease

Belite Bio, Inc - American Depositary Shares  (BLTE) 
PDF Belite expects to complete the new drug application submission in the second quarter of 2026Rolling submission initiated under Breakthrough Therapy Designation SAN DIE [Read more]